Back to discover

Protein / target

Surface antigen (HBsAg)

Q81158Hepatitis B virus
11
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Membrane fusion involved in viral entry into host cell

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Subcellular location

Virion membrane
Domains and Gene Ontology detail (4)

Gene Ontology

  • Cvirion membrane
  • Pmembrane fusion involved in viral entry into host cell
  • Psymbiont entry into host cell
  • Pvirion attachment to host cell

226 aa · 25 kDa

Approved medicines with mapped indications

1 medicine · 2 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Hepatitis B1 medicine
Hepatitis B, Chronic1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

hepatitis B immune globulin
Narrow target profileBinding agent

Surface antigen (HBsAg) binding agent

Indicated for Hepatitis B, Hepatitis B, Chronic

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

11

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (7)

COMPLETED · via hepatitis B immune globulin · NCT02312531

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2009-11-30

    Approval: Zutectra (EMA)

    ema · regulatory · ema · via hepatitis B immune globulin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.